Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D.
H.R. 5539 - Orphan Cures Act
H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access.
Issues related to the diagnosis and treatment of Tardive Dyskinesia.
Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432.
H.R. 7085 - BIOSECURE Act.
Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024.
Duration: September 1, 2019
to
present
General Issues: Medicare/Medicaid , Health Issues , Budget/Appropriations , Taxation/Internal Revenue Code , Insurance
Spending: about $12,730,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Dave Boyer Sp. Ast. Pres LA, Ast Com Leg, FDA; Sp ASt Sec HHS, Con Asst, Off of WH Liaison DoD, Con Asst, Off of Sec Lab.
Sp. Ast. Pres LA, Ast Com Leg, FDA; Sp Ast Sec HHS, Con Asst, Off of WH Liaison DOD, Con Asst, Off of Sec Lab.
Steve Silvestri Office of Representative Frelinghyusen Senior Legislative Assistant: February 2018-November 2018; Legislative Assistant: June 2017-February 2018; Legislative Correspondent: June 2015-June 2017; and Scheduler: June 2013-June 2015.
Valarie Molaison Office of Senator Tester, Congressional Science Fellow (Sep 2011 - Aug 2012); Office of Senator Brown, Health Legislative Assistant (Aug 2012 - Jan 2015)
Aaron Cohen Chief of Staff & Legislative Assistant, Sen. John Ensign; Legislative Aide, Sen. Richard Bryan; Legislative Correspondent, Sen. Richard Bryan.
Timothy Clark n/a
Tim Clark n/a
Steve Silvest n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on April 22.
Original Filing: 301576356.xml
Lobbying Issues
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D.
H.R. 5539 - Orphan Cures Act
H.R. 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access.
Issues related to the diagnosis and treatment of Tardive Dyskinesia.
Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432.
H.R. 7085 - BIOSECURE Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support appropriations report language and funding to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Research and Development (R&D) tax credit including the Tax Relief for American Families and Workers Act of 2024, H.R. 7024.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2023
In Q4, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on Jan. 22.
Original Filing: 301539355.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D;
H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access;
Issues related to diagnosis and treatment of Tardive Dyskinesia;
Issues related to diagnosis and treatment of Parkinsons Disease.
Issues related to Telehealth;
H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth;
H.R.3432 - Telemental Health Care Access Act of 2023.
H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act;
H.R. 6000 Cures 2.0.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2023
In Q3, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on Oct. 20, 2023.
Original Filing: 301511901.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D;
H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access;
Issues related to diagnosis and treatment of Tardive Dyskinesia;
Issues related to diagnosis and treatment of Parkinsons Disease.
Issues related to Telehealth;
H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth;
H.R.3432 - Telemental Health Care Access Act of 2023.
H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act;
H.R. 6000 Cures 2.0.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2023
In Q2, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301487424.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D;
H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access;
Issues related to diagnosis and treatment of Tardive Dyskinesia;
Issues related to diagnosis and treatment of Parkinsons Disease.
Issues related to Telehealth;
H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth;
H.R.3432 - Telemental Health Care Access Act of 2023.
H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act;
H.R. 6000 Cures 2.0.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2023
In Q1, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301467275.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D;
H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access;
Issues related to diagnosis and treatment of Tardive Dyskinesia;
Issues related to diagnosis and treatment of Parkinsons Disease.
Issues related to Telehealth;
S. 2061 Telemental Healthcare Access Act of 2021;
H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth;
H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act;
H.R. 6000 Cures 2.0.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2022
In Q4, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on Jan. 20, 2023.
Original Filing: 301439892.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D;
H.R.5376 - Inflation Reduction Act of 2022 - issues related to implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access;
Issues related to diagnosis and treatment of Tardive Dyskinesia;
Issues related to diagnosis and treatment of Parkinsons Disease.
Issues related to Telehealth;
S. 2061 Telemental Healthcare Access Act of 2021;
H.R.2617 - Consolidated Appropriations Act, 2023 - issues related to telehealth;
H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act;
H.R. 6000 Cures 2.0.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5376 - Inflation Reduction Act of 2022 - Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2022
In Q3, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on Oct. 20, 2022.
Original Filing: 301414263.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D;
HR 3 Elijah E. Cummings Lower Drug Costs Now Act;
S. 2543 Prescription Drug Pricing Reduction Act of 2019;
S.2327 - Seniors Prescription Drug Relief Act;
H.R. 5260 - Reduced Costs and Continued Cures Act;
H.R. 5376 Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access;
Issues related to diagnosis and treatment of Tardive Dyskinesia;
Issues related to diagnosis and treatment of Parkinsons Disease.
Issues related to Telehealth;
S. 2061 Telemental Healthcare Access Act of 2021;
H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act;
H.R. 6000 Cures 2.0.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376 Build Back Better Act - Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
In Q2, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301389855.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D;
HR 3 Elijah E. Cummings Lower Drug Costs Now Act;
S. 2543 Prescription Drug Pricing Reduction Act of 2019;
S.2327 - Seniors Prescription Drug Relief Act;
H.R. 5260 - Reduced Costs and Continued Cures Act;
H.R. 5376 Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access;
Issues related to diagnosis and treatment of Tardive Dyskinesia;
Issues related to diagnosis and treatment of Parkinsons Disease.
Issues related to Telehealth;
S. 2061 Telemental Healthcare Access Act of 2021;
H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act;
H.R. 6000 Cures 2.0.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376 Build Back Better Act - Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2022
NEUROCRINE BIOSCIENCES, INC amended a lobbying report for in-house lobbying in Q12022 on June 13, 2022
Original Filing: 301376425.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376 Build Back Better Act - Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2022
In Q1, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301365148.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376 Build Back Better Act - Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2021
NEUROCRINE BIOSCIENCES, INC amended a lobbying report for in-house lobbying in Q42021 on June 13, 2022
Original Filing: 301376424.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 4439/S.4010, Creating Hope Reauthorization Act; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376 Build Back Better Act - Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2021
In Q4, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on Jan. 20, 2022.
Original Filing: 301331621.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 Reduced Costs and Continued Cures Act; H.R. 5376 Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 4439/S.4010, Creating Hope Reauthorization Act; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act; H.R. 6000 Cures 2.0.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376 Build Back Better Act - Issues related to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2021
In Q3, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on Oct. 20, 2021.
Original Filing: 301308032.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019; S.2327 - Seniors Prescription Drug Relief Act; H.R. 5260 Reduced Costs and Continued Cures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; S. 2061 Telemental Healthcare Access Act of 2021; H.R. 4439/S.4010, Creating Hope Reauthorization Act; H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on July 20, 2021.
Original Filing: 301284593.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Telehealth; H.R. 4439/S. 4010, Creating Hope Reauthorization Act; H.R. 2507 / S. 2158, Newborn Screening Saves Lives Reauthorization Act; and S. 2061, Telemental Healthcare Access Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301260129.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D; Elijah E. Cummings Lower Drug Costs Now Act; Prescription Drug Pricing Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access; diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Telehealth; Creating Hope Reauthorization Act; Newborn Screening Saves Lives Reauthorization Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support from the Department of Health and Human Services for Tardive Dyskinesia patients.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on Jan. 19, 2021.
Original Filing: 301235870.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D;
HR 3 Elijah E. Cummings Lower Drug Costs Now Act;
S. 2543 Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access;
Diagnosis and treatment of Tardive Dyskinesia;
Diagnosis and treatment of Parkinsons Disease;
Issues related to Telehealth;
H.R. 4439/S.4010, Creating Hope Reauthorization Act;
H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on Oct. 19, 2020.
Original Filing: 301215970.xml
Lobbying Issues
Potential changes to structure and reimbursement for Medicare Part D;
HR 3 Elijah E. Cummings Lower Drug Costs Now Act;
S. 2543 Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access;
Diagnosis and treatment of Tardive Dyskinesia;
Diagnosis and treatment of Parkinsons Disease;
Issues related to Telehealth;
H.R. 4439/S.4010, Creating Hope Reauthorization Act;
H.R. 2507/S.2158, Newborn Screening Saves Lives Reauthorization Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on July 20, 2020.
Original Filing: 301200470.xml
Lobbying Issues
H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act.
S.2543 Prescription Drug Pricing Reduction Act of 2019.
Structure and reimbursement for Medicare Part D.
Access to and reimbursement for telemedicine.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access;
Diagnosis and treatment of Tardive Dyskinesia;
Diagnosis and treatment of Parkinsons Disease
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
NEUROCRINE BIOSCIENCES, INC amended a lobbying report for in-house lobbying in Q22020 on July 20, 2020
Original Filing: 301200552.xml
Lobbying Issues
H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act.
S.2543 Prescription Drug Pricing Reduction Act of 2019.
Structure and reimbursement for Medicare Part D.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access;
Diagnosis and treatment of Tardive Dyskinesia;
Diagnosis and treatment of Parkinsons Disease
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on April 20, 2020.
Original Filing: 301175524.xml
Lobbying Issues
H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act.
S.2543 Prescription Drug Pricing Reduction Act of 2019.
Structure and reimbursement for Medicare Part D.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access;
Diagnosis and treatment of Tardive Dyskinesia;
Diagnosis and treatment of Parkinsons Disease
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on Jan. 21, 2020.
Original Filing: 301127356.xml
Lobbying Issues
HR 3 Elijah E. Cummings Lower Drug Costs Now Act;
Potential changes to structure and reimbursement for Medicare Part D.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Regulatory and legislative health care issues impacting pricing and access
Issues related to diagnosis and treatment of Tardive Dyskinesia
Issues related to diagnosis and treatment of Parkinsons Disease
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, NEUROCRINE BIOSCIENCES, INC had in-house lobbyists. The report was filed on Jan. 21, 2020.
Original Filing: 301127343.xml
Lobbying Issues
H.R. 3 is the Elijah E. Cummings Lower Drug Costs Now Act
Lobbying on the Medicare Part D benefit redesign section of the bill.
Agencies Lobbied
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...